Login to Your Account



Other News To Note


Wednesday, November 30, 2011
• BioLineRx Ltd., of Jerusalem, said it received approval from Indian regulators to start the Phase II/III CLARITY trial of BL-1020, an oral GABA-enhanced antipsychotic for treating schizophrenia. Overall, the study is expected to be conducted at about 18 sites in India, 14 sites in Romania and four sites in Israel.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription